论文部分内容阅读
中国医药行业龙头老大——哈药集团有限公司(以下简称哈药,控股哈药集团00604)与中国华源集团(以下简称华源)重组的消息,最近在证券市场引起一连串震荡: 新年前,一篇关于“卖掉哈药”的文章,导致哈药、华源股票停牌一天;而后又有消息说哈药以9.7亿元净资产与华源的10亿元资产重组,华源控股47％,成为第一大股东。1月14日,哈药集团在证券市
Recently, the leader of China's pharmaceutical industry, Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as Harbin Pharmaceutical Group, Holding Harbin Pharmaceutical Group 00604) and China Huayuan Group (hereinafter referred to as Huayuan) reorganized recently and caused a series of shocks in the securities market: An article on “selling Harbin Pharmaceutical” led to Harbin Pharmaceutical, Huayuan Stock suspension of one day; then there is news that Harbin Pharmaceutical to 970 million yuan net assets and Huayuan 1 billion yuan assets restructuring, Huayuan Holdings 47% , Becoming the largest shareholder. January 14, Harbin Pharmaceutical Group in the securities market